The Central government of India has taken a decisive step to safeguard public health by imposing a ban on 14 fixed-dose combinations (FDC) drugs, including well-known medications such as Nimesulide and Paracetamol tablets and Chlopheniramine Maleate and Codeine syrup. This significant move comes in response to the risk these drugs pose to individuals, as highlighted by the Union Health Ministry.

The notification issued by the Ministry emphasizes that there is "no therapeutic justification" for these FDC medicines. Fixed-dose combination drugs refer to formulations that contain a combination of two or more active pharmaceutical ingredients (APIs) in a fixed ratio. The decision to ban these drugs follows the recommendations put forth by an expert committee, which thoroughly examined the available evidence and assessed the potential risks associated with these medications.

Among the banned drugs are those commonly used to treat various ailments such as common infections, cough, and fever. The list includes Nimesulide and Paracetamol tablets, Chlopheniramine Maleate and Codeine Syrup, Pholcodine Promethazine, Amoxicillin Bromhexine, Bromhexine Dextromethorphan Ammonium Chloride Menthol, Paracetamol Bromhexine Phenylephrine Chlorpheniramine Guaiphenesin, and Salbutamol Bromhexine.

The expert committee's evaluation concluded that there is no valid therapeutic justification for the use of these FDC drugs and that they may pose risks to human health. In the interest of public safety and well-being, the notification declares it necessary to prohibit the manufacture, sale, or distribution of these FDCs under section 26A of the Drugs and Cosmetics Act, 1940. The notification unequivocally states that any form of regulation or restriction to allow the use of these drugs in patients is not justifiable.

By acting on the recommendations of the expert committee and the Drugs Technical Advisory Board, the Central government affirms its conviction that regulating and prohibiting the manufacture, sale, and distribution of these drugs is essential and expedient in the interest of public welfare. The government's decision aims to ensure that these drugs, deemed potentially risky and lacking therapeutic justification, are not available for human use in the country.

This ban reinforces the government's commitment to safeguarding public health and underscores the importance of evidence-based medicine and stringent regulatory measures in the pharmaceutical sector. It serves as a reminder of the government's responsibility to prioritize the well-being and safety of its citizens and maintain the highest standards of healthcare. Individuals are encouraged to consult their healthcare providers to explore suitable alternative medications and treatments.

Combination drugs are formulations that contain two or more active pharmaceutical ingredients in a single dosage form. While some combination drugs are effective and widely used, there have been concerns about the proliferation of irrational combinations and the potential risks associated with them. The ban aims to curb the sale, distribution, and use of such combination drugs to protect the health and well-being of the general public.

The banned combination drugs are used in the treatment of common ailments such as respiratory tract infections, pain management, and gastrointestinal disorders. The decision to ban these medications was made after careful evaluation of scientific evidence, clinical data, and expert opinions. The government has emphasized that the ban is intended to promote rational drug use, encourage the use of safer and more effective alternatives, and prevent the misuse or overuse of combination drugs.

Pharmaceutical companies and healthcare professionals have been notified about the ban and directed to stop the production, distribution, and sale of the banned drugs immediately. Patients who are currently using these medications are advised to consult their healthcare providers for alternative treatment options.

The government's decision to ban these 14 combination drugs aligns with its commitment to ensuring the availability of safe, effective, and rational medications for the Indian population. It highlights the importance of evidence-based medicine, pharmacovigilance, and regulatory measures in safeguarding public health.

It is essential for individuals to stay informed about such regulatory actions and work closely with healthcare professionals to make informed decisions about their treatment plans. The ban serves as a reminder of the government's dedication to protecting the well-being of its citizens and maintaining high standards of healthcare in the country.

The drugs mentioned have been used in various cases for the treatment of different ailments. Here are some common cases in which these drugs have been utilized:

1. Nimesulide and Paracetamol tablets:

   • Management of pain and inflammation associated with conditions like arthritis, musculoskeletal disorders, and dental pain.
   • Relief of fever and mild to moderate pain due to viral or bacterial infections.

2. Chlopheniramine Maleate Codeine Syrup:

   • Cough suppression and symptomatic relief of upper respiratory tract infections.
   • Alleviation of allergy symptoms such as runny nose, sneezing, and itchy/watery eyes.

3. Pholcodine Promethazine:

   • Treatment of persistent and irritating dry cough.
   • Reduction of cough reflex sensitivity and associated discomfort.

4. Amoxicillin Bromhexine:

   • Combination therapy for respiratory tract infections, particularly those caused by susceptible bacteria.
   • Bromhexine, when used in combination, can help in clearing mucus and phlegm from the airways.

5. Bromhexine Dextromethorphan Ammonium Chloride Menthol:

   • Relief of cough and congestion associated with common cold, bronchitis, or other respiratory conditions.
   • Dextromethorphan acts as a cough suppressant, while bromhexine aids in breaking down and expelling mucus.

6. Paracetamol Bromhexine Phenylephrine Chlorpheniramine Guaiphenesin:

   • Relief of symptoms related to the common cold, flu, and upper respiratory tract infections.
   • Paracetamol reduces fever and pain, bromhexine helps with mucus clearance, phenylephrine provides nasal congestion relief, chlorpheniramine reduces allergy symptoms, and guaiphenesin aids in cough expectoration.

7. Salbutamol Bromhexine:

   • Management of asthma and chronic obstructive pulmonary disease (COPD) symptoms, including bronchospasm and wheezing.
   • Salbutamol acts as a bronchodilator, relaxing the airway muscles, while bromhexine assists in clearing mucus.

It is important to note that the availability and usage of these drugs may vary based on the regulations and guidelines set by different countries' health authorities. It is always recommended to consult a healthcare professional for appropriate advice and guidance regarding specific medication needs.

2016 | Ban on the manufacture, sale, and distribution of 344 drug combinations

In 2016, the Indian government took a significant step toward ensuring the safety and efficacy of pharmaceutical drugs by announcing a ban on the manufacture, sale, and distribution of 344 drug combinations. This decision came after an expert panel, established under the guidance of the Supreme Court, concluded that these combinations were being sold to patients without sufficient scientific data to support their use. However, the order faced legal challenges from the manufacturers, leading to a prolonged court battle.

The expert panel carefully evaluated the 344 drug combinations and determined that their sale and usage lacked scientific justification. This raised concerns about potential health risks and the need for stringent regulatory measures to protect the public. The ban aimed to curb the indiscriminate use of these combinations and encourage the pharmaceutical industry to provide scientific evidence supporting their safety and efficacy.

Fast forward to the present, and the recently banned 14 fixed-dose combinations (FDC) drugs are a part of the previously identified 344 drug combinations. The decision to ban these 14 FDCs is an extension of the government's commitment to addressing the issues surrounding irrational drug combinations and ensuring the welfare of the population.

By including these 14 FDC drugs in the ban, the government reiterates its stance on the necessity of scientific evidence to support the use of combination medications. The aim is to prevent the availability and usage of drugs that have little therapeutic justification or may pose risks to human health.

It is important to note that the legal battle surrounding the ban on the initial 344 drug combinations reflects the complexity of regulating the pharmaceutical industry. The manufacturers challenged the ban in court, potentially arguing for the safety and efficacy of the combinations or questioning the regulatory processes involved.

The government's commitment to upholding public safety and improving the quality of healthcare remains at the forefront of these regulatory actions. The ban serves as a reminder of the ongoing efforts to establish evidence-based medicine, prioritize patient well-being, and ensure that pharmaceutical products meet the highest standards of quality and efficacy.

References:

indianarrative.com